Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two doses of rituximab before transplant may shield children from Epstein-Barr virus

NCT ID NCT07693881

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This trial tests whether giving two doses of rituximab before a stem cell transplant can prevent Epstein-Barr virus (EBV) from reactivating in children. EBV is a common virus that can cause serious illness in children with weakened immune systems after transplant. The study compares children who receive rituximab plus standard care to those who receive standard care alone, tracking EBV levels and side effects for six months after transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rituximab
What this could lead to
If it works, this approach could reduce serious EBV-related complications in children receiving half-matched stem cell transplants, making the procedure safer.
What could go wrong
This is a relatively small, early-stage trial, and rituximab may cause side effects like infusion reactions or increased risk of other infections. The benefit may not be confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 106 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ECOG performance status score of 0-1, or Karnofsky Performance Status (KPS) score \> 80. * Diagnosis of a disease that has an indication for allogeneic hematopoietic stem cell transplantation. * Donor source is a related HLA haploidentical (half-matched) family donor. * Use of an "ATG-based" transplantation conditioning/protocol. * Written informed consent obtained from the patient's legal guardian prior to enrollment in this study. Exclusion Criteria: * Lansky performance score \< 60. * Diagnosis of EBV-associated hemophagocytic lymphohistiocytosis (HLH) or chronic active EBV infection. * Serum EBV DNA level \> 100 U/mL before transplantation. * Use of B-cell depleting immunotherapy (e.g., rituximab, blinatumomab, etc.) within 2 weeks prior to preconditioning. * Known allergy or hypersensitivity to rituximab. * Severe organ dysfunction * The subject or their legal guardian is unwilling or unable to comply with the protocol, or refuses to sign the informed consent document. * Patients deemed by the investigator to be unsuitable for participation in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV infection after allogenic HSCT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection disease arising from reactivation of latent virus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV infection after allogenic HSCT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    RECRUITING

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.